Primary sclerosing cholangitis behaves differently depending on whether IBD comes along with it.
Hamdan S. AlGhamdi, Nawaf M. AlYahya, Ibrahim M. Bahabri, et al.
Comparing 87 Saudi patients with primary sclerosing cholangitis, this study found that those with concurrent inflammatory bowel disease were diagnosed at a younger age but had less severe liver decompensation than those without IBD. Non-IBD patients showed higher rates of diabetes, autoimmune hepatitis, and hepatic decompensation, yet overall survival was similar between the two groups. Age and MELD-Na score at diagnosis, rather than IBD status, were the strongest predictors of mortality.
- The question: Does inflammatory bowel disease change how PSC behaves?
- The study: Researchers compared 87 Saudi patients with primary sclerosing cholangitis by their IBD status.
- The finding: Patients with concurrent IBD were diagnosed at a younger age but had less severe liver decompensation, while those without IBD showed higher rates of diabetes, autoimmune hepatitis, and hepatic decompensation.
- The nuance: Despite those differences, overall survival was similar between the two groups.
Takeaway: age and MELD-Na score at diagnosis, not IBD status, were the strongest predictors of mortality.
Narrated (standard AI voice, not a cloned voice) with burned-in captions matching the narration word-for-word — safe to watch muted. Built from this article’s SGA Briefing only.
This links to the publisher’s open-access copy of record. A self-hosted PDF will appear here once one is on file.